ArcherDx Seeking Broader Reach for Cancer Diagnostic
Jan 9, 2019 @ 9:28

"The Boulder, CO-based company said its diagnostic assay is a sequencing-based test analyzing more than 50 genes intended for detection of somatic alterations in circulating tumor DNA (ctDNA) present in plasma and in RNA or DNA derived from formalin fixed paraffin embedded (FFPE) cancer tissue.

Results of the ArcherDX companion diagnostic assay will be used to identify patients diagnosed with advanced non-small cell lung cancer for whom treatment with a specific targeted therapy is being considered. If approved, the company said this test could be the first FDA-approved multi-gene sequencing-based in-vitro diagnostic (IVD) to accept both plasma and FFPE-based inputs."

Sourced through from:

Leave a Reply